Brazil's government contracts attracting Big Pharma; Perez to follow Bonney as Cubist CEO;

@FiercePharma: Top-read special report over the weekend: The top 10 most expensive drugs of 2013. Feature | Follow @FiercePharma

@EricPFierce: India's Ascend sold laxatives to urea creams the #FDA never approved. It's now headed for incineration. Article | Follow @EricPFierce

@CarlyHFierce: Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results. Press release | Follow @CarlyHFierce

> The FDA has approved labeling with abuse-deterrent features for Pfizer's ($PFE) Embeda, an extended-release opioid analgesic. Release

> Government contracts guaranteeing market share in Brazil are starting to attract companies like Roche ($RHHBY), Novartis ($NVS) and Sanofi ($SNY). Report

> Canada will allow for sale more than 40 drugs from three Indian factories recently slapped from import bans now that Health Canada has deemed them "medically necessary." More

> Robert Perez will succeed Michael Bonney at the helm of Cubist Pharmaceuticals ($CBST), effective Jan. 1. More

> Ranbaxy staffers will get a year-long pay-cut shield in the Sun Pharmaceuticals buyout. Report

Medical Device News

@FierceMedDev: Quest and LabCorp won't accept blood samples from suspected patients. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Invitae raises $120M to offer cheap, easy genetic analysis. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI last week: Boston Scientific wins CE mark for MRI-friendly pacemaker products. Report | Follow @EmilyWFierce

@MichaelGFierce: Stealthy, DNA-based 'nano-cocoons' deliver cancer-killing payloads. FierceDrugDelivery story | Follow @MichaelGFierce

> Nanodevices could be unleashed by DNA-brick self-assembly. Article

> Abbott seals a deal with Zeiss to sell cataract surgery products. Report

Biotech News

@FierceBiotech: PureTech reels in $55M to fund new biotech bets. News | Follow @FierceBiotech

@JohnCFierce: Top 10 Phase III disasters of 2014. Feature | Follow @JohnCFierce

@DamianFierce: ICYMI Friday: Early look at Adaptimmune's cancer immunotherapy data: 1 complete response and 3 partials among 5 patients. Article | Follow @DamianFierce

@EmilyMFierce: TesoRx licenses oral low-T drug to Aspen amid FDA crackdown. Story | Follow @EmilyMFierce

> Cubist CEO Bonney hands over reins as new buyout rumors circulate. Item

> Celgene's $2.6B deal for Crohn's drug pays off with promising PhII. Report

> Genentech pays $150M upfront to partner on NewLink's immuno-oncology drug. Article

CRO News

> Charles River debuts new testing tech for quality control. News

> Big CROs are booming, but can it last? Item

> A glitch in bioequivalence software puts trial results in doubt. More

> INC signs on to help Provectus get its regulatory act together. Article

> PPD pairs off with Sellas to pick up the pipeline pace. Story

Biotech IT News

> Regeneron allies with DNAnexus on 100,000 exomes project. News

> Report: Novo Nordisk to file for IT unit IPO in coming days. Item

> Researchers join forces to build database of 50M genetic variants. More

> Genomics England picks 10 firms for next round of bioinformatics talent contest. Story

> EMA to discuss possible glitch in Thermo bioequivalence software. Article

Animal Health News

> Blaze wins NCI funding for 'tumor paint' after successful dog study. News

> Canadian Government funds Elanco genomics project. Story

> FDA cracks down on Little City Dogs' compounded copies of popular pet meds. Article

> Report: Pork industry group responds to antibiotic documentary with online campaign. More

> Five questions for Aratana CEO Steven St. Peter. Editor's Corner

And Finally... Aspirin boosts schizophrenia treatments, a new study shows. More

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…